



Regioselectivity of Pictet–Spengler cyclization: synthesis of halotetrahydroisoquinolines

Su-Dong Cho,^{a,*} Sang-Yong Song,^a Eun-Joo Hur,^a Ma Chen,^a Woo-Hong Joo,^a J. R. Falck,^b Yong-Jin Yoon^c and Dong-Soo Shin^{a,*}

^aDepartment of Chemistry, Changwon National University, Changwon, 641-773, South Korea

^bDepartment of Biochemistry, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA

^cDepartment of Chemistry, Gyeongsang National University, Chinju 660-701, South Korea


Received 24 May 2001; revised 29 June 2001; accepted 2 July 2001

Abstract—The regioselectivity of the Pictet–Spengler cyclization for the synthesis of isoquinolines depends on the aryl substituent at C-2. The ratio of halotetrahydroisoquinoline **4** to isoquinoline **3** increases with increasing electrophilicity of the aromatic ring ($H < I < Br < Cl$). © 2001 Elsevier Science Ltd. All rights reserved.

The Pictet–Spengler condensation of *N*-protected phenethylamines with aldehydes is a well known synthetic method for the construction of isoquinolines. This condensation proceeds most smoothly when the phenethyl aromatic ring is activated by electron donating substituents. However, α -phenethylamines bearing an electron withdrawing aryl substituent like acyl^{1a–d} or sulfonyl^{2a–d} are still amenable to Pictet–Spengler cyclization, although yields are variable. Generally, the least sterically hindered *ortho* position is the predominant site of cyclization unless blocked by a substituent at C-2 (Scheme 1). The latter is often a halogen that is subsequently removed in order to obtain a 7,8-disubstitution pattern.

Orazi et al.^{2a} was one of the first to exploit a sulfonyl

group as the *N*-substituent for a Pictet–Spengler condensation. Also, Kohno et al.^{3a–b} reported the reaction of *N*-benzenesulfonyl- α -phenethylamines with ethyl chloro(methylthio)acetate in the presence of SnCl₄ affords isoquinolines. Silveira et al.⁴ carried out similar cyclizations using β -halo- α -phenylselenyl esters. Notably, few examples of asymmetric Pictet–Spengler condensations have been published. For instance, Piper et al.⁵ reported the addition of dopamine hydrochloride with D-glucose in aqueous solution gave a chiral tetrahydroisoquinoline in excellent yield. Similarly, Czarnocki et al.⁶ observed that the treatment of *N*-glyoxyoly-(2*R*)-bornane-10,2-sultam with dopamine hydrochloride furnished a chiral isoquinoline.



Scheme 1.


Keywords: Pictet–Spengler; condensation; cyclization; halotetrahydroisoquinoline.

* Corresponding authors. Tel.: (+82)-55-279-7433; e-mail: dsshin@sarim.changwon.ac.kr

During the course of our studies directed at the synthesis of substituted 5-halotetrahydroisoquinolines **4**, we turned our attention to the regioselectivity of 2-halophenethylamines **1a–d** in Pictet–Spengler condensations with acetals or aldehydes under Lewis acidic conditions (Scheme 1).

The starting material, sulfonamide⁷ **1a** (X=H), was easily prepared from the corresponding phenethylamine by addition of methanesulfonyl chloride. Halogenation of **1a** according to literature procedures gave rise to 2-halosulfonamides **1b–d** in good yields (Scheme 2). Specifically, chlorosulfonamide **1b** (X=Cl) was readily prepared via reaction of **1a** with $\text{CuCl}_2/\text{Al}_2\text{O}_3/\text{chlorobenzene}$ ⁸ (91%), bromosulfonamide **1c** (X=Br) using NBS/DMF⁹ (93%), and iodosulfonamide **1d** (X=I) (88%) utilizing $\text{CuCl}_2/\text{Al}_2\text{O}_3/\text{I}_2$.¹⁰

As anticipated, condensation of sulfonamide **1a** with bromoacetaldehyde diethyl acetal (**2a**) in CH_2Cl_2 and cyclization of the adduct using boron trifluoride diethyl etherate complex or conc. H_2SO_4 at room temperature for 1 hour afforded **3a** as the sole product in excellent yield (Table 1). Following literature precedent, introduction of a chloride at C-2 as in **1b**, completely altered the regiochemical selectivity to give **4b** in 90% yield accompanied by a trace of **3a** (0.2%). On the other hand, Pictet–Spengler cyclization of **1c** with **2a** resulted in a mixture of **3a** and **4c**, although the latter cyclization mode still predominates. In contrast, iodo derivative **1d** was the least regioselective and produced a virtually equimolar mixture of **3a** and **4d**. Replacement of $\text{BF}_3 \cdot \text{Et}_2\text{O}$ with mineral acids (H_2SO_4 , HCl) and various other Lewis acids did not influence the cyclization yield.



Scheme 2.

Table 1. The yields and ratio of 3/4 by Pictet–Spengler condensation of **1** and **2**

Entry	1, X		Aldehyde(or Acetal), 2	3/4, R		Yield(%) ^a of 3/4	Ratio ^b of 3/4
	a	X		3	4		
1	a	H	2a 	3a/4a	-CH ₂ Br	95	100/0
	b	Cl		3a/4b		90	0.2/99.8
	c	Br		3a/4c		92	5.0/95.0
	d	I		3a/4d		89	41.1/58.9
2	a	H	2b 	3b/4e	-H	83	100/0
	b	Cl		3b/4f		88	0.1/99.9
	c	Br		3b/4g		91	6.8/93.2
	d	I		3b/4h		89	23.9/76.1
3	a	H	2c 	3c/4i	-CO ₂ -(l)-Menthyl	89	100/0
	b	Cl		3c/4j		81	0/100
	c	Br		3c/4k		76	12.8/87.2
	d	I		3c/4l		83	61.4/38.6
4	a	H	2d 	3d/4m	-CH ₂ C ₆ H ₅	67	100/0
	b	Cl		3d/4n		58	0.2/99.8
	c	Br		3d/4o		65	28.2/71.8
	d	I		3d/4p		75	51.2/48.8
5	a	H	2e 	3e/4q	-CH ₂ CH ₂ C ₆ H ₅	58	100/0
	b	Cl		3e/4r		55	0.1/99.9
	c	Br		3e/4s		70	41.5/58.5
	d	I		3e/4t		62	96.7/3.3

^a Isolated yield after flash chromatography.

^b Determined via the analysis of the GC-MS spectra.

^c L-Menthyl 2,2-dihydroxyacetate was synthesized in Kg scale in our lab.

Inspection of Table 1 reveals a similar reactivity pattern for dimethylacetal **2b**. Total yields for aldehydes **2c–e** are somewhat reduced, but they still reflect the same regioselectivity pattern. In general, the ratio of isoquinoline **3** to halotetrahydroisoquinoline **4** depends on the identity of the halo-substituent at C-2 on the aromatic moiety, regardless of the reaction conditions and condensation partner. The percentage of halotetrahydroisoquinoline **4** increased in the order $H \ll I < Br < Cl$, i.e. with increasing electrophilicity.

In conclusion, we have described a Pictet–Spengler cyclization strategy to prepare halotetrahydroisoquinolines **4** based upon the C-2 halogen substituent. Applications of this strategy to the syntheses of biologically active compounds are under investigation and will be reported in due course.

Typical procedure: $BF_3 \cdot OEt_2$ (3.2 mL, 25.6 mmol, 3.5 equiv.) was slowly added to a solution of bromosulfonamide **1c** (2.47 g, 7.3 mmol, 1.0 equiv.) and **2a** ($R = -CH_2Br$) (1.03 mL, 8.7 mmol, 1.2 equiv.) in dichloromethane 20 mL and stirred at room temperature under N_2 atmosphere for 1 hour. The reaction mixture was poured into cold water and extracted twice with dichloromethane (30 mL). The combined organic extracts were washed water and dried over $MgSO_4$. The solution was concentrated under reduced pressure and the residue was purified by column chromatography on silica gel using *n*-hexane:ethyl acetate (1/1) as eluent to afford **3a/4c** (92% yield) as white solid. **3a**: mp 143–144°C; 1H NMR (300 MHz, $CDCl_3$) δ 6.64 (s, 1H), 6.61 (s, 1H), 5.05–5.10 (q, 1H), 3.85–3.92 (m, 1H), 3.87 (s, OCH_3), 3.86 (s, OCH_3), 3.60–3.72 (m, 2H), 3.42–3.52 (m, 1H), 3.00–3.08 (m, 1H), 2.99 (s, 3H), 2.67–2.74 (m, 1H); MS (*m/z*) 364.

4c: mp 156–157°C; 1H NMR ($CDCl_3$) δ 7.11 (s, 1H), 5.12–5.22 (s, 1H), 3.91–3.94 (m, 1H), 3.85 (s, OCH_3), 3.80 (s, OCH_3), 3.63–3.78 (m, 2H), 3.40–3.49 (m, 1H),

3.24–3.26 (m, 1H), 3.07 (s, 3H), 2.72–2.90 (m, 1H); MS (*m/z*) 443.

Acknowledgements

The authors thank the Korea Research Foundation (KRF), the Institute of Basic Science of Changwon National University for a postdoctoral fellowship, the Robert A. Welch Foundation, and NIH (GM31278).

References

1. (a) Mollow, M. M.; Venkov, A. P. *Synthesis* **1978**, 62; (b) Venkov, A. P.; Lukanov, L. K. *Synthesis* **1989**, 59; (c) Lazarus, S.; Wittekind, R. R. *J. Heterocycl. Chem.* **1971**, 8, 495; (d) Comins, D. L.; Badawi, M. M. *Tetrahedron Lett.* **1991**, 32, 2995.
2. (a) Orazi, O. O.; Corral, R. A.; Giaccio, H. *J. Chem. Soc., Perkin Trans. 1* **1986**, 1977; (b) Zinczuk, J.; Sorokin, I. H.; Orazi, O. O.; Corral, R. A. *J. Heterocycl. Chem.* **1992**, 29, 859; (c) Lukanov, L. K.; Venkov, N. M. *Synthesis* **1987**, 204; (d) Ito, K.; Tanaka, H. *Chem. Pharm. Bull.* **1977**, 25, 1732.
3. (a) Kohno, H.; Sekine, Y. *Heterocycles* **1996**, 42, 141; (b) Kohno, H.; Yamada, K. *Heterocycles* **1999**, 51, 103.
4. Silveria, C. C.; Bernardi, C. R.; Braga, A. L.; Kaufman, T. S. *Tetrahedron Lett.* **1999**, 40, 4969.
5. Piper, I. M.; Maclean, D. B. *Can. J. Chem.* **1983**, 61, 2721.
6. Czarnocki, Z.; Mieczkowski, J. B.; Kiegiei, J.; Arazny, Z. *Tetrahedron: Asymmetry* **1995**, 6, 2899.
7. Bobbitt, J. M.; Chair, T. T. *J. Org. Chem.* **1959**, 24, 1106.
8. Kodomari, M.; Takahashi, S.; Yoshitomi, S. *Chem. Lett.* **1987**, 1901.
9. Outten, R. A.; Daves, Jr., G. D. *J. Org. Chem.* **1987**, 52, 5064.
10. Kodomari, M.; Amanokura, N.; Takeuchi, K.; Yoshitomi, S. *Bull. Chem. Soc. Jpn.* **1992**, 65, 306.